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Ibuprofen reduces energy expenditure and acute-phase protein production
compared with placebo in pancreatic cancer patients
SJ Wigmore, JS Falconer, CE Plester, JA Ross, JP Maingay, DC Carter and KCH Fearon
University Department ofSurgery, Royal Infirmary ofEdinburgh, Edinburgh EH3 9YW, UK.
S_mmary The aim of this study was to investigate the effect of the cyclo-oxygenase inhibitor ibuprofen on
the acute-phase protein response and resting energy expenditure (REE) of weight-losing patients with panc-
reatic cancer. Patients with irresectable pancreatic cancer (n = 16) were treated with either ibuprofen
(1200 mg day-' for 7 days (n = 10) or placebo (n = 6). A group of 17 age-related non-cancer subjects were also
studied. Indirect calorimetry, anthropometry, multifrequency bioelectrical impedence analysis and serum
C-reactive protein (CRP) estimation were performed immediately before and after treatment. Before treatment,
total REE was significantly elevated in the pancreatic cancer patients compared with healthy controls
(1499 ± 71 vs 1377 ± 58 kcal) (P<0.02). Following treatment the mean REE of the ibuprofen group fell
significantly (1386 ± 89 kcal) compared with pretreatment values (1468 ± 99 kcal) (P<0.02), whereas no
change was observed in the placebo group. Serum CRP concentration was also reduced in the ibuprofen-
treated group (pre-ibuprofen, 51 mgl'; post-ibuprofen, 29mgI '; P<0.05). These results suggest that
ibuprofen may have a role in abrogating the catabolic processes which contribute to weight loss in patients
with pancreatic cancer.
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More than 90% ofpatients with pancreatic cancer experience
weight loss during the course of their disease, and in many
cachexia is the dominant feature (De Wys et al., 1986). The
cancer cachexia syndrome is complex and involves features
such as anorexia and asethenia, early satiety and hyper-
catabolism (Fearon, 1992). Although anorexia and malab-
sorption are important factors contributing to the weight loss
observed in patients with pancreatic cancer, the degree of
wasting cannot be explained simply by a reduction in nutri-
tional intake. It has been demonstrated (Falconer et al.,
1994) that patients with pancreatic cancer have significantly
elevated resting energy expenditure and that the most
hypermetabolic are those with an ongoing hepatic acute-
phase protein response (APPR). The APPR is thought to be
mediated by proinfammatory cytokines such as tumour nec-
rosis factor (TNF) and interleukin 6 (IL-6) (Heinrich, 1990),
which in turn have been shown to be capable of mediating a
syndrome similar to cancer cachexia in animals (Tracey et al.,
1988; Strassmann et al., 1993). Furthermore, infusion of
TNF has been shown to increase energy expenditure in man
(Starnes et al., 1988).
The mediators of the APPR in cancer and their role in
producing the variety of metabolic changes associated with
cachexia remain unclear. Interleukin 6, interleukin Ip and
tumour necrosis factor alpha have all been implicated as
potential mediators of the APPR through both direct and
prostaglandin-mediated pathways (Heinrich, 1990). Prostag-
landins are thought to have an important role in regulating
the inflammatory response. We propose that the prostaglan-
din-cytokine axis might be a potential target for therapeutic
intervention in patients with cancer cachexia and that
inhibiting the inflammatory response might result in reduc-
tions in both the hepatic acute-phase response and energy
expenditure. Ibuprofen is a non-steroidal anti-inflammatory
agent and a potent cyclo-oxygenase enzyme inhibitor which
is known to inhibit some of the end-organ effects of the
proinflammatory cytokines. In particular, ibuprofen has been
shown to reduce body temperature and the metabolic rate of
patients with burn injury (Wallace et al., 1992) and to reduce
the level of the acute-phase response in some patients with
rheumatoid arthritis (Cash et al., 1990). This study inves-
tigates the effect of treatment with ibuprofen or placebo on
energy expenditure and acute-phase protein production in
patients with pancreatic cancer.
Materik and mthods
Patients
A consecutive series of 16 patients with histologically proven
adenocarcinoma of the pancreas with evidence of weight loss
were entered into the study. None of the patients had under-
gone surgery in the preceding 2 months. All patients were
judged on the basis of clinical evaluation to be free from
metabolic or endocrine disorders. None of the patients was
jaundiced, pyrexial or had clinical or radiological evidence of
infection, or was severely anaemic. In addition, none of the
study patients had a history of recent non-steroidal anti-
inflammatory drug usage or was taking steroid drugs. All
patients had adequate pain control at the time of study. Ten
paitents were allocated treatment with ibuprofen, and values
for REE and CRP were compared before and after treat-
ment. To exclude the possibility that either disease progres-
sion or familiarity with the method of indirect calorimetry
could account for the observed reductions in REE, six
patients with pancreatic cancer were given a placebo and
measurements of REE and CRP performed before and after
treatment. Patients receiving ibuprofen therapy took 1200 mg
each day in three divided doses for 7 days. The six patients
received one placebo tablet three times each day for 7 days.
Consent was obtained from each patient and ethical approval
to conduct the trial was obtained from the local ethical
committee. A group of 17 healthy subjects, comprising
preoperative elective admissions for minor surgery with non-
malignant disease, was studied as a control group for com-
parison with the pancreatic cancer patients.
Measurement ofC-reactive protein
Venous blood samples were collected immediately before and
after 7 days of treatment with ibuprofen. Serum samples for
plasma protein analysis were stored frozen at - 70C until
measurement. A sandwich enzyme-linked immunosorbent
assay (ELISA) was employed for the measurement of C-
reactive protein (CRP). Briefly, 96-well immunolates (Costar,
UK) were coated with goat anti-human CRP (Dako, High
Wycombe, UK). Sera, diluted 1:10 for CRP, were added to
wells in triplicate and incubated at 4°C for 18 h. The secon-
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dary antibody was rabbit anti-huIman CRP (Dako, High
Wycombe, UK). This was dett by peroxdas-conjugated
antibody diected against rabbit immunoglobulins (Sigma,
Poole, UK) and the substrate 3,3',5,5- ta hylbenzidine.
The plates were read at 490 nm using a MR5000 ELISA
plate reader (Dynatech, Billinghurst, UK), and concentra-
tions in the samples were alclated usng the AssayZap
(Biosoft, Cambrige, UK) computer software. The limit of
sensitivity ofthe assays, taking into consideration the sample
dilutions, was 120 pgml-' for CRP.
Nutritional Assessment
Baseline anthropometry, body composition analysis and
energy expenditure were assessed as described below in all
patients and controls. Nutritional assessment was repeated in
the two patient groups following administration for I week
of either ibuprofen 1200mgday-' or placebo.
Anthropometry At the initial assessment, height, pre-iliness
stable weight and duration of weight loss were recorded.
Subjects were weighed on spring balance scales (Seca, Ger-
many) without shoes and wearing light clothing. Ideal body
weight was calculated using standardised tables (Metro-
politan Life Assurance Tables). Mid-upper arm circum-
ference was measured at the midpoint between the olecranon
and acromion processes. Mid-arm muscle circunference
(MAMC) was calculated using Jelliffe's equation. (Jelliffe,
1966). Triceps skinfold thickness (TSF) was measured using
Harpenden calipers (Holtain, UK). Three measurements were
performed and the mean value recorded.
Body composition analysis Multiple frequency bioelectrical
impedence analysis (MFBIA) (Xitron 4000 MFBIA Xitron
Technologies, San Diego, CA, USA) operated at a current of
200p.A root mean square was used to assess body composi-
tion. All values were recorded with the subject supine with
limbs apart. Repeat mesurements were performed using the
same pair of limbs. Total body resistance and reactance were
taken at 4, 50 and 500 kHz. Values for total and extracellular
water spaces were obtained using equations validated in a
similar patient group (Hannan et al., 1994). Fat-free mass
(FFM) was calculated from total body water (TBW) assum-
ing a constant hydration of 73.2% (Pace and Rathburn,
1945).
Resting energy expenditure Resting energy expenditure was
measured by indirect calorimetry using a ventilated hood
system (Deltatrac; S&W Vcwkers, UK). All recordings were
conducted in a thermoneutral environment between 08.00
and 09.00 hours following an overnight fast with the patient
lying supine and at rest. Before measurement the equipment
was calibrated using gas containing 95% oxygen and 5%
carbon dioxide at a known barometric pressure. Flow
through the canopy was kept constant at 44.31min-'. Gas
analysis was performed using a paramagnetic oxygen
analyser and an infra-red carbon dioxide analyser. Vo2 and
Vc02 were measured over a 201mm period and processed
on-line by a microprocessor and converted to mean energy
expenditure using the abbreviated de Weir formula (de Weir,
1949). This system provides measurements of Vo2 and Vco2
which have an error of less than 4% (Makita et al., 1990).
Values are expressed per patient and in relation to total body
weight and lean body mass. During the course of the study
change in weight was incorporated, on an individual basis, in
calculations of predicted energy expenditure and body com-
position analysis.
Statistics
Values are presented as mean ± standard error of the mean
(s.e.m.). Statistical analysis was performed using either a
paired or unpaired Student's two-tailed t-test for com-
parisons between variables and groups as indicated. A P-
value of less than 0.05 was conidered siifint.
Redts
Patient characteristics
The nutritional status, body composition and resting energy
expenditure of the 16 pancreatic cancer patients before treat-
ment and of the 17 healthy control subjects are detailed in
Table I. In contrast to the weight-stable non-cancer controls,
the pancreatc cancer patients had sustai substantial
weight loss (mean 17% ofprevious stable weight), with upper
arm anthropometry suggesting that both subcutaneous fat
and skeletal muscle mass were reduced. Body composition
analysis using MFBIA confirmed that the pancreatic cancer
patients had a signiantly different body composition to
that observed in the healthy non-ncer control group.
Although total body water was similar between the groups,
the cancer patients had significantly lower fat-free mass than
non-cancer patients.
Measurements of resting energy expenditure demonstrated
that the recorded REE for the cancer patients was
signifintly higher than values for healthy non-cancer sub-
jects (Table I) (mean total REE 1499 ± 71 vs 1377 ± 58 kcal
24h-1, P<0.02). Values of total REE (P<0.02), REE per
kg body weight (P<0.05) and REE per kg fat-free mass
(P<0.002) fell siificntly from pretreatment values after 7
days oftherapy with ibuprofen 1.2 gday-' (Table III). In the
group treated with ibuprofen, reduction in total REE follow-
ing treatment resulted in a mean value which was not
signiiantly different from that of healthy controls (REE
1386 ±89 vs 1377 ± 58 kcal day-'). In the group of patients
who received plaebo no changes in REE were observed
Table I Nutritional statusand bodycomposition ofpancreaticcancer
patients (n = 16) and healthy non-cancer controls (n = 17)
Pancreatic Healthy
cancer controls P
Age 60± 2.3 56± 3.5 NS
Sexratio M:F 10:6 12:5 NS
Weight (kg) 58.6 3.8 71.9 3.5 <0.05
Percmtage ofideal body 88 3.6 108 4.3 <0.001
weight'
Weight os as a percentage 17 1.4 Nil <0.001
ofprevious stable weight
Total body water () 37.5 1.3 39.5 1.7 NS
Fat-free mass (kg) 42.8 ± 2.8 52.5 ± 2.5 <0.0001
Triceps skinfold thicknessb 64.3 ± 4.1 87.5 ± 5.3 <0.001
(percentage ofreference)
Mid-armcircumference' 91 ± 5.3 102 4.8 <0.05
(percentage ofreference)
REE total kcal 24h-' 1499 71 1377 58 <0.02
REEkcal kg-' body weight 25.58±12 19.15 0.7 <0.001
REE kcal kg-' fat free mass 35.0 0.9 26.2 0.5 <0.001
NS, not significant (unpaired Student's t-test). aMetopoltan Life
Assuran Tables. bJelIiffe et al. (1966).
Tabe I Nutrtional status and body composition of the pancratic
cancer patiets before treatment with ibuprofen (n = 10) or placebo
(n = 6)
rprofen Placelo P
Age 59±2.1 62±3.5 NS
Sexratio M:F 7:3 3:3 NS
Weight (kg) 58.6 3.8 58.8 5.6 NS
Weight kssas a percentage 16 1.4 18 1.9 NS
ofprevious stable weight
Total body water (1) 38.8 ± 2.7 35.3 _ 2.5 NS
Fat-free mass (kg) 42.8 _ 2.8 43.0 4.0 NS
Body cell mass (kg) 23.2 2.0 22.0 1.5 NS
Triceps skinfold thicknessa 62.5 2.7 67.0± 3.1 NS
(percentage ofreference)
Mid-arm circumference 87 6.3* 95 4.2 <0.05
(percentage ofreference)
NS, not sgnificnt (unpaired Student's t-test). aJelhffe et al., 1966.(Table 1II).
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There was no significant difference between the would be to remove the tumour and allow spontaneous
*eated and placebo-treated cancer patients with recovery of nutritional status (Calman. 1982). but this is
ge. weight loss, triceps skinfold thickness or body rarely feasible (Carter. 1989). Since decline in nutritional
(Table II). The placebo-treated group had a status is so closely associated with morbidity and mortality in
higher mid-arm muscle circumference than the pancreatic cancer patients. modulation of the inflammatory
reated group (P<0.05). and catabolic processes which underlie weight loss may offer
-reactive protein concentrations in the patients substantial benefits in terms of duration of survival and
after treatment with ibuprofen are shown in quality of life.
Aeasurement of serum C-reactive protein in the In this study we have demonstrated that patients with
roup demonstrated concentrations of more than pancreatic cancer have significantly elevated REE compared
in three patients before commencement of with healthy non-cancer subjects (Table I). Treatment with a
P titres fell in nine out of ten patients following 7 day course of ibuprofen resulted in a statistically significant
ith ibuprofen. One patient experienced a marked reduction of about 6% in REE (Table III). In contrast. REE
' from 20 to 63 mg 1' after treatment. and this was unchanged during the course of the studv in a matched
uld not easily be explained by sepsis or tissue group of pancreatic cancer patients treated with placebo
e mean CRP of the ibuprofen-treated group fell (Table I1I). The reduction in REE that occurred after treat-
2 to 29 ± 2 mg 1- (P<0.05. two-tailed t-test). ment with ibuprofen amounted to approximately 80 kcal per
rotein was not detected in the sera of any of the patient per dav. Over a 6 month period. this would reduce a
trol group. patient's energy deficit by about 14 60 kcal or the equivalent
of about 2 kg of adipose tissue. Whether the effect of ibupro-
fen on REE would be maintained over a period of many
months and what the clinical significance of such a change
would be has yet to be ascertained.
options for pancreatic cancer patients are ex- In addition to an elevated energ- expenditure. the pan-
nited. Approximately 90f00 of patients have creatic cancer patients had an elevated serum C-reactive pro-
tumours or metastatic disease at the time of tein concentration (mean 51 mg 1I) when compared with
Carter. 1989). Despite recent improvements in healthy controls (undetectable). This reinforces the previously
id staging. the prognosis remains very poor with described observation of an association between elevation of
survival time of 3 -6 months. Patients with REE and persistent activation of the hepatic acute-phase
oma of the pancreas have among the highest protein response in weight-losing patients with cancer (Fal-
f weight loss of any group of cancer patients. coner et al.. 1994). In the present study. the reduction in
ributes to the morbidity and mortality of this REE observed in the ibuprofen-treated patients was
Wys. 1986). The majonty of therapeutic paralleled by a significant reduction in serum C-reactive pro-
ve concentrated on reduction in tumour burden. tein concentration (Figure 1). During semistarvation the
Lttention has been directed toward limiting or amino acids to support acute-phase protein synthesis come
chexia. Clearly the best way to treat cachexia from the breakdown of skeletal muscle, and it has been
pointed out that the amino acid composition of skeletal
muscle differs considerably from that of the common acute-
phase proteins (Reeds et al.. 1994). This means that a pro-
portion of amino acids mobilised from skeletal muscle will be
oxidised. and the transfer of amino acids from one tissue to
another will lead to a net loss of nitrogen from the body.
Whether the observed attenuation of the acute-phase res-
ponse induced by ibuprofen (Figure 1) might improve
significantly the overall nitrogen economy of the wasted
cancer patient will require further long-term studies.
Ibuprofen is a non-steroidal anti-inflammatory drug with
potent inhibitory action on the enzyme cyclo-oxygenase. It is
known to inhibit some of the end-organ effects of the pro-
inflammatory cytokines IL-6. IL-1 and TNF (Dinarello and
Wolff. 1982: Durum et al.. 1985). It has been suggested that
the proinflammatorv cytokines IL-6. IL-1 and TNF-x.
released by cells of the macrophage monocyte series (Auger
1 2 3 4 5 6 7 8 9 10 ana Koss. lWil)may be responslble tor the mcreasedenergy expenditure and altered nitrogen metabolism that is thought Patient number to contribute to weight loss and shortened survival in cancer
bhanges in serum C-reactive protein in ten patients patients (Fearon and Carter. 1988; Fearon et al., 1991).
gically confirmed carcinoma of the pancreas as deter- Recently this hypothesis has been supported by the demon-
ELISA before (U) and after (0) treatment with stration that weight-losing patients with pancreatic cancer
-1 ibuprofen for 7 days. have a chronically elevated hepatic acute-phase response and
Table III Recorded resting enern-expenditure (REE) values before and after treatment with ibuprofen
1.2 g day' or placebo for 1 w-eek
Ibuprofen group Placebo group
n= 10 n=6
Pre-treatment Post-treatment P Pre-treatment Post-treatment P
REEtotal 1468 99 1386 89 <0.02 1518 61 1564 77 NS
REE 25.62 0.9 24.53 ± 0.6 <0.05 25.55 ± 0.4 26.02 0.7 NS
(kcal kg' BW)
REE 35.18 ± 1.0 33.12 +2.4 <0.002 34.83 2.6 35.22 +2.4 NS
(kcalkg-' FFM)
FFM. fat-free mass. Statistical significance Ispretreatment -alues. NS. notsignificant(Student's paired
t-test).
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that this is associated with an increased resting energy expen-
diture compared with healthy controls (Falconer et al., 1994).
A further indication of the importance of the presence of an
acute-phase response in patients with pancreatic cancer is
given by the observation that duration of survival is closely
associated with the presence or absence of an elevated serum
CRP titre at the time of diagnosis and that this is independ-
ent of stage of disease (Falconer et al., 1995).
The mechanism of reduction of acute-phase protein pro-
duction by ibuprofen is uncertain. It might be that ibuprofen
reduces production of the proinflammatory cytokines such as
IL-6, IL-1 and TNF, which are known to stimulate acute-
phase protein production by hepatocytes. It is uncertain
whether administration of ibuprofen results in a reduction in
circulating cytokines in cancer patients. However, there is
evidence to suggest that this may be the case in sepsis, with
pretreated patients with ibuprofen showing an attenuated
TNF response to endotoxin challenge (Spinas et al., 1991;
Matrich et al., 1991). Previous studies have demonstrated,
however, paradoxical elevation of proinflammatory cytokine
production by isolated peripheral blood mononuclear cells
following treatment with ibuprofen (Kunkel et al., 1986;
West et al., 1993). Ibuprofen may down-regulate acute-phase
protein production via a prostaglandin-mediated pathway,
resulting in reduced responsiveness to proinflammatory
cytokines, or via direct effect on hepatocyte protein produc-
tion.
This study provides evidence that even relatively short
periods of treatment with ibuprofen can significantly reduce
both resting energy expenditure and hepatocyte acute-phase
protein expression. Further studies are required to elucidate
whether the use of cyclo-oxygenase inhibitors can alter
weight loss over a more protracted period or influence sur-
vival.
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